FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
OC10 | FROM DESIGN TO CLINICAL PHASE 3 IN ONCOLOGY: CD13-TARGETED TISSUE FACTOR AND TUMOR INFARCTION W.E. Berdel, C. Schwöppe, C. Brand, K. Hessling, A.F. Berdel, T. Kessler, G. Lenz, R.M. Mesters, C. Schliemann | Department of Medicine A, University Hospital, Muenster, Germany
502PDF: 105 -
PO35 | A MULTICENTRE AUDIT OF CURRENT TUMOUR THROMBOSIS MANAGEMENT IN THE UNITED KINGDOM A.A. Bhatti1, L. Tafesh1, A. Waton1, M. Thomas3, N. Prasannan3, A. Bhide3, R. Walsh3, T. Lucas3, K. White4, T. Bariana4, O. Tsiamita4, S. Soman4, P. Woolley5, I. Lacej5, K. Musgrave1|2 | 1Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 2Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; 3University College London Hospitals NHS Foundation Trust, London, UK; 4Barts Health NHS Trust, London, UK; 5Imperial College Healthcare NHS Trust, London, UK
485PDF: 102 -
PO22 | LONG-TERM ANTICOAGULANT THERAPY AND REDUCTION OF OVARIAN CANCER RECURRENCE: CLINICAL EVIDENCE OF A POTENTIAL ANTITUMOUR EFFECT J. Khizroeva1, V. Bitsadze1, A. Vorobev1, A. Solopova1, M. Tretyakova1, N. Gashimova1, K. Grigoreva1, A. Khisamieva1, J. Gris1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University, Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
435PDF: 94 -
OC13 | VON WILLEBRAND FACTOR PREDICTS POOR OUTCOME IN PANCREATIC CANCER AND MEDIATES TUMOR-ENDOTHELIUM INTERACTIONS FACILITATING METASTASIS B. Ünlü1, Z. Zhao1, N. Joshi1, S. De1, A. Chion1, I. Schoen1, J. O’Donnell1, M. Flick2, M. Fishel3|4, J. O’Sullivan1 | 1School of Pharmacy and Biomolecular Sciences, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland; 2UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, USA; 3IU Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA; 4Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
495PDF: 100 -
PO01 | MELANOMA-DERIVED EXTRACELLULAR VESICLES DRIVE VON WILLEBRAND FACTOR–DEPENDENT THROMBOSIS AND METASTASIS Y. Wang1|2, X. Liu1, T. Downar3, A. Topuz4, A. Bauer1, J. Kött1|5, K. Nekipelov6, S. Brenna7, G. Bendas6, B. Puig7, S. Schneider1, D. Fedosov4, C. Gorzelanny1 | 1Department of Dermatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 3Experimental Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 4Institute for Advanced Simulation (IAS-2), Forschungszentrum Jülich, Jülich, Germany; 5Fleur Hiege Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6Pharmaceutical Institute, University of Bonn, Bonn, Germany; 7Neurology Department, Experimental Research in Stroke and Inflammation (ERSI), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
512PDF: 116 -
CO011 | GENERATION OF A TARGETING NON-BLOCKING TISSUE FACTOR ANTIBODY FOR SAFE AND EFFICACIOUS CANCER TREATMENTS A. Metelli1, P. Nisticò1, J. Wrangle2 | 1IRCCS Regina Elena National Cancer Institute, Roma, Italy; 2Medical University of South Carolina, Charleston, USA
151PDF: 21 -
PO67 | TARGETED THERAPIES FOR CANCER AND THE RISK OF ARTERIAL AND VENOUS THROMBOEMBOLISM O. Iqbal | Loyola University Stritch School of Medicine, Maywood, IL, USA
508PDF: 115 -
CO010 | MAPPING HEMOSTATIC BIOMARKER EXPRESSION ACROSS CANCER TYPES AND STAGES WITHIN THE HYPERCAN COHORT P. Gómez-Rosas1|2, D. Romeo1, S. Bolognini1, C. Ticozzi1, F. Schieppati1|4|5, A. D’Alessio3, R. Labianca3, L. Barcella1|4|5, A. Falanga3|5, M. Marchetti1|4|5 | 1Hospital Papa Giovanni XXIII, Bergamo, Italy; 2Hospital de Oncología, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México, México; 3Fondazione ARTET Onlus, Bergamo, Italy; 4ERN EuroBloodNet; 5School of Medicine and Surgery, University of Milan Bicocca, Italy. On behalf of the HYPERCAN Investigators
143PDF: 27 -
PO61 | RISK FACTORS FOR INTRACRANIAL HEMORRHAGE: AN UMBRELLA REVIEW TO INFORM MACHINE LEARNING PREDICTION MODELS IN GLIOMA PATIENTS RECEIVING ANTICOAGULATION T.A. Adeyemo, S. Greenley, F. Ware, W. Jones, A. Maraveyas, F. Haque | 1Centre of Excellence for Data Science, Artificial Intelligence and Modelling DAIM, Faculty of Science and Engineering, University of Hull, UK; 2Hull York Medical School, Hull, UK; 3Academic Library Services, University of Hull, UK; 4NHS Humber Health Partnership, Hull, UK
542PDF: 118 -
CO-84 | PARAPROTEIN-DRIVEN ACQUIRED VON WILLEBRAND SYNDROME IN A PATIENT WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND UROTHELIAL CARCINOMA A. Ierardi, A. Strangio, M. Leotta, R.C. Santoro | Hemostasis Unit, AOU Dulbecco, Catanzaro, Italy
49PDF: 24 -
PO42 | DIFFERENTIAL EXPRESSION OF HEMOSTATIC BIOMARKERS ACROSS CANCER TYPE AND DISEASE STAGE: A PROSPECTIVE ANALYSIS OF 4,292 PATIENTS FROM THE HYPERCAN STUDY P. Gómez-Rosas1|2|, D. Romeo1, S. Bolognini1, C. Ticozzi1, F. Schieppati1, A. D’Alessio4, R. Labianca4, A. Falanga1|5|6, M. Marchetti1|5|6 | 1Hospital Papa Giovanni XXIII, Bergamo, Italy; 2Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; 3Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; 4Fondazione ARTET Onlus, Bergamo, Italy; 5ERN EuroBloodNet; 6School of Medicine and Surgery, University of Milan Bicocca, Italy; *On Behalf Of The Hypercan Investigators
533PDF: 117 -
PO34 | A negative oncologic follow up doesn’t always really mean no cancer: two case report of cancer-associated thrombotic microangiopathy E. Cosi, A. Bertomoro, G. Bogoni, I. Bertozzi, I. Cortella, P. Simioni | Clinica Medica ORI, Azienda Ospedale-Università Padova, DIDAS, Italy
614PDF: 35 -
PO05 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NOVEL IMATINIB AND NILOTINIB ANALOGUES EXPRESSING ENHANCED ANTIPLATELET AND ANTICANCER ACTIVITIES D. Pantazi1, L. Pechlivani1, A. Kosma1, K. Lalechou1, M.G. Siskos2, D. Alivertis3, A.D. Tselepis1 | 1Atherothrombosis Research Centre, Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Greece; 2Laboratory of Organic Chemistry, Department of Chemistry, University of Ioannina, Greece; 3Department of Biological Applications and Technology, University of Ioannina, Greece
570PDF: 108 -
PO109 | A RARE CASE OF ANEMIA AND THROMBOCYTOPENIA E. Cosi, A. Bertomoro, I. Bertozzi, G. Bogoni, M. Zerbinati, A. Galbiati, G. Antonello, D. Lovison, P. Simioni | Department of Medicine, University of Padua, Italy
54PDF: 26 -
PO04 | FIBRIN CLOT SHIELDS PROMOTE CLONAL SELECTION IN CANCER CELLS: PROCOAGULANT ACTIVITY AND SURVIVAL OF CLOT-EMBEDDED CELLS. A NOVEL TUMOR MICROENVIRONMENT MODEL M.A. Baghdadi1|2, E. Mbemba1, P. Las Casa1, P. Van Dreden1|3, N. Saleem1|4, J. Fareed4, P. Kempaiah4, M. Sabbah1, G. Gerotziafas1|4 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology, Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris, France; 2Research Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia; 3Diagnostica Stago, Gennevilliers, France; 4Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA
490PDF: 101 -
Platelet-driven remodeling of cancer cell glycoproteins fuels inflammation and metastasis
558PDF: 148Extra Tables: 75Extra Figure 1: 78Extra Figure 2: 67 -
PO31 | MIGRATORY SUPERFICIAL THROMBOPHLEBITIS REFRACTORY TO APIXABAN IN A PATIENT WITH LUNG ADENOCARCINOMA I. Goldberg1|2, P. Raanani1|2|3, G. Spectre1|2 | 1Institute of Hematology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel; 2Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; 3Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel
510PDF: 104 -
PO87 | Intravascular leiomyomatosis extending to the right atrium: a case report with a multidisciplinary management M. Iorio1,2, C. Cavallaro1,2, E. Butera1,2, R. Talerico1,2, A. Gasbarrini2,3, R. Pola1,2 | 1Department of Aging, Orthopedic, and Rheumatologic Sciences, Agostino Gemelli Polyclinic Foundation Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma; 2Università Cattolica del Sacro Cuore, Roma; 3Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
650PDF: 22 -
PO51 | Thrombocythemia associated with a non-canonical JAK2 mutation: a case report G. Rosati, A. Pozzi, M. Padrini, S. Laurenti, G. Ferrari, R.M. Medici, C. Barale, I. Russo, A. Morotti | University of Turin, AUO San Luigi Gonzaga, Orbassano (TO), Italy
768PDF: 23 -
PO003 | CATHETER-RELATED THROMBOSIS IN CANCER PATIENTS: A RETROSPECTIVE REAL-WORLD STUDY G. Autiero1|3, S.A. Malerba1|2|4, F. Busato1|2, D. Tolomio1|2, M. Dalla Vestra1|2, F. Presotto1|2 | 1U.O. Medicina Generale, Osp. Dell'Angelo, Venezia-Mestre, Italy; 2U.O. Angiologia, Osp. Dell'Angelo, Venezia-Mestre, Italy; 3Dip. Medicina Interna, Università degli Studi di Padova, Italy; 4U.O.C. Medicina Generale ad indirizzo trombotico ed emorragico, Università degli studi di Padova, Italy
45PDF: 26 -
PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker1, M. P. O’Brien2, M. Carrier3, J. Connors4, A. Falanga5, A. Manzano6, R. Mcbane7, Y.Y. Janjigian1, G. O’Kane8, M. Onisko2, J. Kaplan2, A.P. Kithcart2, D.E. Gutstein2, A. Khorana9, M. F. Walsh2 | 1Memorial Sloan Kettering Cancer Center, New York, USA; 2Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 3University of Ottawa, Ottawa, ON, Canada; 4Harvard Medical School, Boston, MA, USA; 5Hospital Papa Giovanni XXIII, Bergamo, Italy; 6Hospital Universitario 12 de Octubre, Madrid, Spain; 7Mayo Clinic, Rochester, MN, USA; 8St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; 9James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
540PDF: 126 -
PO125 | ROMIPLOSTIM FOR CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA IN ADVANCED SOLID TUMORS: A SINGLE-CENTER EXPERIENCE G. Giustini1, A. Baffioni1, C. Giubbilei1, A.M. Vannucchi2, V. Carrai3 | 1SOD Ematologia, Università degli studi di Firenze, Italy; 2Center for Research and Innovation of Myeloproliferative Neoplasms, SOD Ematologia, AOU Careggi, Università degli studi di Firenze, Italy; 3SOD Ematologia, Dipartimento di Oncologia, AOU Careggi, Firenze, Italy
46PDF: 24 -
CO-73 | WHEN BLEEDING MIMICS THROMBOSIS: DIAGNOSTIC DELAY AND THROMBOTIC COMPLICATIONS IN ACQUIRED HEMOPHILIA A R. Tomasello1, M. Mattana1, S. Raso1, F. Schirò1, P. Polidori2, M.I. Di Lena3, F. La Gattuta4, M. Napolitano1 | 1Ematologia e malattie rare, PO Cervello di Palermo, Italy; 2Farmacia ospedaliera, PO Cervello di Palermo, Italy; 3Direzione medica, PO Cervello di Palermo, Italy; 4Radiologia interventistica, PO Villa Sofia di Palermo, Italy
70PDF: 20 -
PO17 | PREDICTIVE VALUE OF INFLAMMATORY AND ENDOTHELIAL BIOMARKERS FOR CANCER RISK IN HEALTHY INDIVIDUALS: EVIDENCE FROM THE HYPERCAN STUDY C. Ticozzi1, S. Bolognini1|2, P. Gomez-Rosas1|3, F. Schieppati1|2, G. Sampietro4, L. Barcella1, M. Marchetti1|2, A. Falanga1|2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands; 4Unit of Epidemiology and Statistics, ATS Bergamo, Italy
458PDF: 104 -
CO074 | WHOLE-BLOOD COAGULATION AND PLATELET DYNAMICS IDENTIFY DIFFERENTIAL PROTHROMBOTIC STATES IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK OR TNFⱭ INHIBITORS L. Spiezia, A. Giollo, L. Di Luozzo, M. Salvato, K. Khalid, R. D’Andrea, A. Benetti, C. Samà, R. Ramonda, P. Simioni | Dipartimento di Medicina, Azienda Osp. Università di Padova, Italy
65PDF: 32 -
PO49 | PROPHYLACTIC ANTICOAGULATION DECISIONS IN HIGH-RISK PATIENTS RECEIVING CANCER-DIRECTED THERAPY: ANALYSIS OF THE VERMONT METHOD J. Barker1, K. Libby1, C. Holmes2, K. Martin2 | 1University of Vermont Health System; 2Department of Medicine, University of Vermont, Burlington, VT, USA
476PDF: 108 -
PO117 | LONGITUDINAL THROMBIN GENERATION PROFILING IN A PATIENT WITH SEVERE HEMOPHILIA A DURING ANTITHROMBIN-LOWERING THERAPY, CANCER, AND MAJOR SURGERY C. Simion, C. Bulato, E. Campello, E. Zanon, B. Serena, S. Toffanin, P. Simioni | Department of Medicine, University of Padova, Italy
56PDF: 26 -
CO-42 | LONGITUDINAL THROMBIN GENERATION PROFILING IN A PATIENT WITH SEVERE HEMOPHILIA A DURING ANTITHROMBIN-LOWERING THERAPY, CANCER, AND MAJOR SURGERY C. Simion1|2, C. Bulato1, E. Campello1|2, E. Zanon1|2, B. Serena1, S. Toffanin1, P. Simioni1|2 | 1First Chair of Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, Padova University Hospital, Italy; 2Hemophilia Center, Padova University Hospital, Italy
67PDF: 19 -
CO14 | Inflammation and fibrinolysis biomarkers as predictors of cancer risk in healthy subjects: results from the hypercan study C. Ticozzi1, S. Bolognini1,2, P. Gomez-Rosas1,3, L. Russo1,2, Cj. Tartari1,2, F. Schieppati1,2, G. Sampietro4, L. Barcella1, M. Marchetti1,2, A. Falanga1,2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Unit of Epidemiology and Statistics, ATS Bergamo, Italy
682PDF: 29 -
CO064 | THROMBOTIC AND BLEEDING EVENTS IN PATIENTS WITH VASCULAR INVASION BY ADVANCED HEPATOCELLULAR CARCINOMA: A SYSTEMATIC REVIEW L. Leoni1, G. Tosti2, F.R. Ponziani2, A. Porfidia2, F. Landi2, A. Gasbarrini2, R. Pola2, F. Santopaolo2, R. Talerico2 | 1Internal Medicine Department, Vita-Salute San Raffaele University, IRCCS, Milano, Italy; 2Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy
67PDF: 23 -
PO053 | PLATELET AGGREGATION AND THROMBIN GENERATION IN MULTIPLE MYELOMA: A PROSPECTIVE STUDY M. Biglietto, M. Mormile, A. Piciocchi, F. Fazio, M. Capriata, S. Sorella, E. Baldacci, A. Chistolini, M.T. Petrucci, C. Santoro | Sapienza University of Roma, Italy
65PDF: 31 -
PO03 | HEPATIC FIBROSIS–DRIVEN TISSUE FACTOR EXPRESSION BY MALIGNANT CHOLANGIOCYTES IS ASSOCIATED WITH CANCER-ASSOCIATED THROMBOSIS AND POOR SURVIVAL IN INTRAHEPATIC CHOLANGIOCARCINOMA L. Fabris1|2|3, Y. Frión-Herrera1, C. Venturin1|3, M. Cadamuro4, J. Gasparello5, C. M. Radu1|2, M. Fassan1|5, C. Mescoli6, U. Cillo7|8, E. Gringeri7|8, G. Zanus7|9, E. Campello1|2, M. Strazzabosco3, P. Simioni1|2 | 1Department of Medicine, University of Padua; 2Clinical Medicine 1 and Thrombotic and Haemorrhagic Disease Unit, and Haemophilia Center, Padua University-Hospital; 3Department of Internal Medicine, Digestive Disease Section, Liver Center, Yale University, New Haven, CT, USA; 4School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy; 5Pathology Unit, Ca' Foncello Hospital, ULSS2 Marca Trevigiana, Treviso; 6Pathology Unit, Padua University-Hospital; 7Department of Surgery, Oncology and Gastroenterology, University of Padua; 8Hepatobiliary Surgery and Liver Transplantation Unit, Padua University-Hospital; 9General Surgery Unit, Ca' Foncello Hospital, ULSS2 Marca Trevigiana, Treviso, Italy
535PDF: 104 -
PO039 | CLINICAL AND LABORATORY CHARACTERISTICS OF ACQUIRED HEMOPHILIA A: PRELIMINARY RESULTS FROM A RETROSPECTIVE OBSERVATIONAL MONOCENTRIC STUDY S. Suardi1, M. Bodini2, A.C. Giuffrida2, A. Zanzanelli3, S. Moruzzi1, L. Delfino1, F. Pizzolo1, S. Genesini2, M. Cantini2, C. Spillere1, L. Panepinto1, F. Zoccatelli1, E. Malloggi1, F. Presa1, A. Moschella1, M. Merlo1, G. Gandini2, S. Friso1, N. Martinelli1 | 1Department of Medicine, Unit of Internal Medicine B, Azienda Ospedaliera Universitaria Integrata di Verona, Italy; 2Department of Transfusion Medicine, Hemophilia Center, Azienda Ospedaliera Universitaria Integrata di Verona, Italy; 3Division of Internal Medicine, IRCCS Azienda Ospedaliero Universitaria Bologna, Italy
54PDF: 25 -
PO02 | SYNERGISTIC INTERACTION OF ENDOTHELIAL AND CANCER CELLS IN THE FORMATION AND STRUCTURE OF THE FIBRIN CLOT SHIELDS M.A. Baghdadi1|2, E. Mbemba1, P. Las Casa1, P. Van Dreden1|3, N. Saleem1|4, J. Fareed4, P. Kempaiah4, M. Sabbah1, G. Gerotziafas1|4 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris France; 2Research Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia; 3Diagnostica Stago, clinical research, Gennevilliers, France; 4Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA
479PDF: 104 -
CO-86 | A RARE CASE OF ACQUIRED HEMOPHILIA A ASSOCIATED WITH MYELOPROLIFERATIVE NEOPLASM A. Ierardi, A. Strangio, M. Leotta, R.C. Santoro | Hemophilia, Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
58PDF: 26 -
PO30 | LONG-TERM ANTICOAGULANT THERAPY AND PREVENTION OF RECURRENT VENOUS THROMBOEMBOLISM IN ADVANCED OVARIAN CANCER V. Bitsadze 1, A. Vorobev 1, J. Khizroeva 1, A. Solopova 1, M. Tretyakova 1, N. Gashimova 1, K. Grigoreva 1, A. Khisamieva 1, J. Gris 1|2, I. Elalamy1|3|4, G. Gerotziafas1|3|4, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 3Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 4Hospital Tenon, Paris, France
484PDF: 101 -
PO008 | HISTORY OF CANCER IN VTE PATIENTS WITH AND WITHOUT HEREDITARY THROMBOPHILIA: A SINGLE CENTER COHORT STUDY A. Napolitano, E. Campello, C. Simion, G. Furlan, S. Gavasso, C. Bulato, C. Samà, S. Toffanin, B. Serena, L. Spiezia, P. Simioni | Department of Medicine, University of Padova, Italy
61PDF: 24 -
PO55 | HISTORY OF CANCER IN PATIENTS WITH SEVERE HEREDITARY THROMBOPHILIA VERSUS NO THROMBOPHILIA: A SINGLE-CENTER COHORT OF PATIENTS WITH VENOUS THROMBOSIS A. Napolitano, E. Campello, C. Simion, G. Furlan, S. Gavasso, C. Bulato, C. Samà, S. Toffanin, B. Serena, L. Spiezia, P. Simioni | Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy
534PDF: 116 -
PO150 | FACTOR XII DEFICIENCY IN THE SETTING OF RECURRENT THROMBOSIS AND EXTENDED VENOUS OBSTRUCTION: A CASE ANALYSIS L. Leoni1, G. Pata1, A. Domenighini1, L. Crippa2, T. D'aliberti1, G. Galimberti1, F. Paciullo1, P. Rovere Querini1 | 1Internal Medicine Unit; 2Coagulation Service Thrombosis Research Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy
43PDF: 24
1 - 52 of 52 items
